Back to Search
Start Over
Propensity-matched comparisons of clinical outcomes after transapical or transfemoral transcatheter aortic valve replacement: a placement of aortic transcatheter valves (PARTNER)-I trial substudy.
- Source :
-
Circulation [Circulation] 2015 Jun 02; Vol. 131 (22), pp. 1989-2000. Date of Electronic Publication: 2015 Apr 01. - Publication Year :
- 2015
-
Abstract
- Background: The higher risk of adverse outcomes after transapical (TA) versus transfemoral (TF) transcatheter aortic valve replacement (TAVR) could be attributable to TA-TAVR being an open surgical procedure or to clinical differences between TA- and TF-TAVR patients. We compared outcomes after neutralizing patient differences using propensity score matching.<br />Methods and Results: From April 2007 to February 2012, 1100 Placement of Aortic Transcatheter Valves (PARTNER)-I patients underwent TA-TAVR and 1521 underwent TF-TAVR with Edwards SAPIEN balloon-expandable bioprostheses. Propensity matching based on 111 preprocedural variables, exclusive of femoral access morphology, identified 501 well-matched patient pairs (46% of possible matches), 95% of whom had peripheral arterial disease. Matched TA-TAVR patients experienced more adverse procedural events, longer length of stay (5 versus 8 days; P<0.0001), and slower recovery (New York Heart Association class I, 31% versus 38% at 30 days, equalizing by 6 months at 51% versus 47%); stroke risk was similar (3.4% versus 3.3% at 30 days and 6.0% versus 6.7% at 3 years); mortality was elevated for the first 6 postprocedural months (19% versus 12%; P=0.01); but aortic regurgitation was less (34% versus 52% mild and 8.9% versus 12% moderate to severe at discharge, P=0.001; 36% versus 50% mild and 10% versus 15% moderate to severe at 6 months, P<0.0001).<br />Conclusions: The likelihood of adverse periprocedural events and prolonged recovery is greater after TA-TAVR than TF-TAVR in vasculopathic patients after accounting for differences in cardiovascular risk factors, although stroke risk is equivalent and aortic regurgitation is less. As smaller delivery systems permit TF-TAVR in many of these patients, we recommend a TF-first access strategy for TAVR when anatomically feasible.<br />Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.<br /> (© 2015 American Heart Association, Inc.)
- Subjects :
- Aged
Aged, 80 and over
Aortic Valve Stenosis diagnosis
Cardiac Catheterization adverse effects
Female
Follow-Up Studies
Humans
Longitudinal Studies
Male
Mortality trends
Transcatheter Aortic Valve Replacement adverse effects
Transcatheter Aortic Valve Replacement trends
Treatment Outcome
Aortic Valve Stenosis mortality
Aortic Valve Stenosis surgery
Cardiac Catheterization mortality
Femoral Artery
Propensity Score
Transcatheter Aortic Valve Replacement mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 131
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 25832034
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.114.012525